Chagas disease is caused by a common parasite in South and Central America and results in 12,000 deaths every year. A pediatric formulation for Chagas has just been developed by Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE) with support from Drugs for Neglected Diseases initiative(DNDi) in 2011. 4th Sector Health, that invests USAID funds to leverage partner contributions and foster greater private sector involvement in health in Latin America and the Caribbean, is partnering with DNDi to develop and disseminate communication materials about the new pediatric dosage in endemic countries. An estimated 8 million people are infected, and 100 million remain at risk in 21 countries across Central and South America. Benznidazole, one of the two treatments for Chagas, is currently only available in an adult dose. In preparation for the availability of the pediatric formulation for patients in mid-2011, 4th Sector Health is supporting the development of an information toolkit to inform health care professionals, patient associations, and caretakers. The initiative aims to inform 70,000 health care professionals in Brazil and 80 percent of the health care staff in endemic regions throughout Latin America on the new pediatric dosage of benznidazole. Materials will be translated into Portuguese and Spanish and given to Ministries of Health across the region, ensuring the initiative's sustainability.
|Location||Latin America and the Caribbean, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, French Guiana, Argentina, Guatemala, Guyana, Honduras, Mexico, Nicaragua, Panama, Paraguay, Suriname, Uruguay, Venezuela|